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ABSTRACT: Bone formation is a carefully controlled developmental process involving morphogen-mediated patterning sig-
nals that define areas of initial mesenchyme condensation followed by induction of cell-specific differentiation programs to
produce chondrocytes and osteoblasts. Positional information is conveyed via gradients of molecules, such as Sonic Hedgehog
that are released from cells within a particular morphogenic field together with region-specific patterns of hox gene expres-
sion. These, in turn, regulate the localized production of bone morphogenetic proteins and related molecules which initiate
chondrocyte- and osteoblast-specific differentiation programs. Differentiation requires the initial commitment of mesenchy-
mal stem cells to a given lineage, followed by induction of tissue-specific patterns of gene expression. Considerable informa-
tion about the control of osteoblast-specific gene expression has come from analysis of the promoter regions of genes encod-
ing proteins like osteocalcin that are selectively expressed in bone. Both general and tissue-specific transcription factors con-
trol this promoter. Osf2/Cbfal, the first osteoblast-specific transcription factor to be identified, is expressed early in the
osteoblast lineage and interacts with specific DNA sequences in the osteocalcin promoter essential for its selective expression
in osteoblasts. The OSF2/CBFAI gene is necessary for the development of mineralized tissues, and its mutation causes the
human disease, cleidocranial dysplasia. Committed osteoprogenitor cells already expressing Osf2/Cbfa 1 must synthesize a col-
lagenous ECM before they will differentiate. A cell:ECM interaction mediated by integrin-type cell-surface receptors is essen-
tial for the induction of osteocalcin and other osteoblast-related proteins. This interaction stimulates the binding of
Osf2/Cbfa 1 to the osteocalcin promoter through an as-yet-undefined mechanism.
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Introduction
An understanding of factors controlling gene expres-
sion in osteoblasts is of particular importance to
dental researchers, both because of the fundamental role
played by bone in the overall structure of oral tissues and
because underlying principles involved in the control of
osteoblasts will likely be relevant to other mineralized
tissues such as dentin and cementum. The goal of this
article is to provide a timely overview of current knowl-
edge regarding early events in bone formation, with
emphasis on the nuclear factors required for the selec-
tive expression of specific genes in osteoblasts and their
regulation by extracellular matrix signals.
The Embryonic Patterning of Bone
There are two broad phases of tissue morphogenesis; an
initial patterning phase, in which cells destined to form
a given tissue are specified in time and space, and the
subsequent induction of the necessary cellular pheno-
types to produce the tissue of interest. These phases are
not mutually exclusive. Rather, cells within a developing
tissue can be viewed as altering the pattern of differenti-
ation of their neighbors through a variety of signals
mediated by diffusible factors, cell:extracellular matrix
interactions, and direct cell:cell contact.
The patterning of bones and teeth has been the sub-
ject of several recent reviews and will not be extensively
discussed in this article (Erlebacher et al., 1995; Thesleff
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Progenitors for other mesenchymal
cells including adipocytes, fibroblasts,
and myoblasts
Figure 1. Proposed steps in the osteoblast lineage implying recognizable stages of differentiation. All mesenchymal lineages are pos-
tulated to be derived from a common stem cell precursor (adapted from Aubin and Lui, 1996).
et al 1995. Johnson and Tabin, 1997). However, a few
common themes will be briefly outlined. The developing
limb bud serves as a good example of the types of inter-
actions necessary for skeletal morphogenesis (Tickle,
1995). Early in limb development, an anterior/posterior
axis is established which specifies the positions of bones
such as the digits of the hand. This axis is determined by
a group of cells in the posterior limb mesenchyme known
as the Zone of Polarizing Activity (ZPA). These cells were
identified by their ability, when transplanted to the ante-
rior side of the limb bud, to induce a mirror-image dupli-
cation of skeletal elements. Sonic Hedgehog (Shh), a
secreted protein, is the key inductive factor produced by
the ZPA. The anterior/posterior asymmetry of limb bones
is thought to be a reflection of the distribution of Shh
throughout the limb bud as it is secreted from the ZPA.
The primary targets of Shh are cells of the apical ecto-
dermal ridge (AER) which, after Shh stimulation, pro-
duce Fibroblast Growth Factor 4 (FGF-4). FGF-4 in turn
stimulates Shh secretion in the mesenchyme underlying
the AER. Shh also stimulates the homeobox gene, hoxd-
13, which is required for normal limb patterning, and
Bone Morphogenetic Protein 2 (BMP2), an inducer of car-
tilage condensation and subsequent bone formation.
Thus, early limb morphogenesis is explained by a recip-
rocal pattern of inductive signals between underlying
limb mesoderm and epithelium (AER) initiated by the
asymmetric distribution of a signal originating from the
ZPA. The overall result of these interactions is specifica-
tion of the positional identity of skeletal elements well
before the initiation of overt skeletogenesis. Recent evi-
dence suggests that similar patterning events may take
place in craniofacial bone formation and tooth morpho-
genesis (Satokata and Maas, 1994).
The initial positional identity of skeletal precursors
is defined by the pattern of expression of a family of tran-
scription factors encoded by homeobox genes (reviewed
in Erlebacher et al., 1995). Consistent with the concept
that they provide positional information, targeted inacti-
vation, mutations, or ectopic expression of homeobox
genes leads to deletion or addition of specific skeletal
structures. For example, inactivation of the hoxa-2 gene
results in deletion of the craniofacial elements derived
from the second branchial arch and their replacement by
elements derived from the first branchial arch (Gendron-
Maguire et al., 1993). The homeotic mutation does not,
therefore, affect bone formation per se. Rather, it alters
the type of bony structure to be formed at a given posi-
tion. The initial pattern defined by the expression of
homeobox genes is further modified by locally secreted
factors such as BMPs. Certain homeotic genes, including
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Figure 2. Relationship between cell growth and differentiation-related gene expression
during the in vitro cultivation of calvarial osteoblasts. The reduction in cell growth and con-
comitant increase in differentiation are indicated by arrows. H4 histone gene expression
is most closely correlated with cell division. Other genes expressed at this time are c-fos
and c-jun (see text). Abbreviations: Col 1, type collagen; AP, alkaline phosphatase; Op,
osteopontin; and OC, osteocalcin. Although Col I mRNA levels are highest during the pro-
liferation phase, matrix deposition continues to increase throughout the entire culture peri-
od (adapted from Owen et al., 1990).
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As osteoprogenitors mature, they
become increasingly restricted in
terms of their proliferative potential.
Because osteoprogenitors do not
express proteins normally associated
with osteoblasts (see below) and have
no morphological characteristics to
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entiation pathway of C2C 12 myoblast from muscle to the
osteoblast lineage (Katagiri et al., 1994), although, in this
study, effects of the BMP were reversible. Recent evi-
dence suggests that glucocorticoids, a second class of
compounds known to increase osteoprogenitors in mar-
row stromal cultures, may actually function by increasing
BMP-6 synthesis (Boden et al., 1997).
It is likely that BMPs are only one of several compo-
nents necessary for the conversion of pluripotent stem
cells to osteoprogenitors. For example, although BMP-2
clearly stimulates osteoblast differentiation in
C3HIOTI/2 mesenchymal cells, it also stimulates forma-
tion of adipocytes and chondrocytes, with adipocytes
being preferentially induced at low BMP concentrations
and chondrocytes and osteoblasts favored at high con-
centrations (Wang et al., 1993). Interestingly, in this study,
the activity of BMP-2 in stimulating formation of
osteoblastic vs. adipogenic colonies could be perturbed
by a number of humoral factors, including insulin,
tumor-derived growth factor-3 (TGF-1), epidermal
growth factor (EGF), leukocyte inhibitory factor (LIF),
fibroblast growth factor-4 (FGF-4), and platelet-derived
growth factor (PDGF). Other factors-such as the cal-
citropic hormone, 1,25-dihydroxyvitamin D3 stimulate
induction of osteoblast characteristics, particularly in
immature cells, and may, therefore, regulate progenitor
formation (Franceschi et al., 1988; Gerstenfeld et al., 1996).
Expression of the Osteoblast Phenotype
in Committed Osteoprogenitor Cells
Osteoprogenitors, while restricted in their lineage poten-
tial, will differentiate into mature, secretory osteoblasts
only if they undergo growth arrest and establish a col-
lagenous extracellular matrix (ECM). In both primary
osteoblast cultures and nontransformed osteoblast cell
lines, expression of differentiation markers follows a
clear temporal sequence (Fig. 2). Genes associated with
cell proliferation-such as H4 histone, C-FOS, and C-
MYC-are expressed at early times along with those
encoding the procxl(l) and proo2(1) propeptides of type I
collagen. Initial collagen matrix accumulation precedes
and is essential for sequential expression of the differen-
tiation-related proteins, alkaline phosphatase, the
PTH/PTHrP receptor, bone sialoprotein, and osteocalcin
(Gerstenfeld et al., 1987; Owen et al., 1990; Franceschi and
Iyer, 1992; Ibaraki et al., 1992; McCauley et al., 1996). A
similar pattern of gene expression is also seen in vivo and
in organ culture; osteoprogenitors adjacent to bone are
highly proliferative and express low levels of bone-spe-
cific proteins, while secretory osteoblasts on the bone
surface stop dividing and produce large amounts of
bone-specific ECM (Strauss et al., 1990; Suva et al., 1993).
As will be discussed later in this article, a complete
model for transcriptional regulation in osteoblasts must
explain the conversion of mesenchymal stem cells to
osteoprogenitors as well as the influences of cell prolif-
eration and ECM synthesis on gene expression.
General Models for the Control
of Tissue-specific Gene Expression
As noted above, the progression from uncommitted stem
cell to osteoprogenitor and finally mature osteoblast and
osteocyte is accompanied by specific changes in gene
expression. A common theme in development is that
specific transcription factors or groups of factors control
the process of lineage commitment by selectively acti-
vating those genes to be expressed in the differentiated
state. Several classes of tissue-specific transcription fac-
tors have been described, including the basic
helix/loop/helix (bHLH) family involved in myogenic,
myeloid, erythroid, and neuronal differentiation (Olson
and Klein, 1994), bHLH leucine zipper factors involved in
adipocyte and liver differentiation (Tontonoz et al., 1993;
Nishiyori et al., 1994), orphan members of the steroid
receptor superfamily such as HNF-4 involved in liver dif-
ferentiation (Nishiyori et al., 1994), and POU-domain fac-
tors involved in pituitary differentiation (Ingraham et al.,
1990).
Several experimental approaches have been suc-
cessfully used to identify transcription factors controlling
tissue-specific gene expression. These approaches can
be divided into two general categories: (1) identification
of factors able to confer a differentiated phenotype on an
undifferentiated cell or tissue, and (2) identification of
promoter elements able to confer tissue-specific expres-
sion on genes associated with a given phenotype, with
subsequent identification and functional testing of
nuclear proteins associating with these elements. The
classic example of the first type of approach is the dis-
covery of MyoD, a muscle-specific bHLH transcription
factor. MyoD was isolated from a cDNA library enriched
for transcripts present in a myogenic clone of C3HlOTI/2
cells that were not present in wild-type undifferentiated
cells. Transfection of MyoD into wild-type C3H1OT1/2
cells induced myotube formation and muscle-specific
gene expression (Weintraub et al., 1991). MyoD was sub-
sequently shown to bind to and activate skeletal muscle-
related genes through a specific DNA element called an
E-box and having the general sequence, CAnnTG. Four
other myogenic bHLH factors (myogenin, myf-5, MRF-4,
and myf-6) were subsequently cloned and shown to be
involved in various steps in myoblast/myotube formation
(Oldberg et al., 1986). Although there is considerable
redundancy between members of the MyoD family, gene
knockout studies with one family member, myogenin,
indicate that this factor is essential for the formation of
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skeletal muscle (Olson and Klein, 1994). Similarly,
neuroD, a second type of bHLH protein, can convert pre-
sumptive epidermal cells into neural cells when its
mRNA is injected into Xenopus embryos (Lee et al., 1995).
An example of the second approach is the isolation of
the hepatocyte-specific factor, HNF-1. This transcription
factor was identified in hepatocyte nuclear extracts by its
ability to bind to an oligonucleotide containing a
sequence in the ornithine transcarbamylase gene pro-
moter previously shown to be essential for liver-specific
expression (Nishiyori et al., 1994).
Although studies on osteoblast gene regulation have
used both of the experimental approaches described
above, investigators have achieved the greatest success in
this area by focusing on specific gene promoters and asso-
ciated nuclear factors. The osteocalcin gene and genes
encoding the pro(xo(I) and proc2(I) chains of type I colla-
gen have been the subject of intense investigation.
Recently, several laboratories have also initiated studies
on the bone sialoprotein gene. The following discussion
will focus on the osteocalcin gene, which contains the
best-understood osteoblast-specific promoter. Recent
developments in our understanding of transcriptional
control of the bone sialoprotein gene will also be briefly
outlined. The type I collagen genes, which are subject to
complex controls in a number of tissues in addition to
bone, have been recently reviewed (Bornstein, 1996; Dodig
et al., 1996b) and will not be discussed in this article.
Transcriptional Regulation
of the Osteocalcin Gene
Of the major osteoblast-related gene products, osteocal-
cin exhibits the most selective pattern of expression; it is
synthesized only by mature osteoblasts, odontoblasts,
and cementoblasts (Bronckers et al., 1987). Thus, control
mechanisms governing its transcription are likely to
include tissue-specific signals. Although the function of
this y-carboxyglutamic acid-containing protein is not
completely understood, gene knockout experiments sug-
gest a role in bone turnover (Ducy et al., 1996). The first
evidence that the osteocalcin gene promoter contained
sufficient information to confer tissue-specific expres-
sion came from studies with transgenic animals. When
3.9 kb of untranscribed 5 sequence from the human
osteocalcin promoter linked to the reporter gene, chlo-
ramphenicol acetyltransferase, was introduced into
transgenic mice, selective expression was observed in
osteoblasts (Kesterson et al., 1993). This promoter region,
therefore, contains sequences necessary for bone-specif-
ic expression. In recent years, investigators have studied
the proximal promoter extensively, with the goal of iden-
tifying sequence elements necessary for basal and
osteoblast-specific expression. These studies followed
two general paths: the identification and functional char-
acterization of elements known to be binding sites for
previously characterized transcription factors, and the
search for new elements, particularly those able to con-
fer an osteoblast-selective pattern of expression and
bind nuclear factors preferentially expressed in
osteoblasts.
Genes being actively transcribed in a particular tissue
are known to exhibit enhanced sensitivity to nucleases
such as DNase I. This increased sensitivity is thought to
reflect absence of the usual nucleosomal chromatin
structure and the presence of specific nonhistone pro-
teins that are required for transcriptional activation.
DNase I digestion of nuclei from ROS 17/2.8 osteoblast-
like osteosarcoma cells identified two hypersensitive
sites in the rat osteocalcin gene promoter, one between
-590 and -390 nucleotides (nt) upstream from the tran-
scription start site, and a second site between - 170 and
-70 nt (Montecino et al., 1994). These sites were not found
in nuclei from hepatoma cells which do not actively tran-
scribe this gene. Inspection of these two regions revealed
the presence of a number of sequence elements, includ-
ing a functional vitamin D regulatory element (VDRE) and
flanking activating protein-l (AP-1) sites in the -590 to
-390 nt region and a rich concentration of known tran-
scription factor binding sites between -170 and -70 nt,
some of which were shown to be active in functional
assays. Within the downstream hypersensitive site are
two E-box sequences, putative binding sites for the bHLH
family of transcription factors (Tamura and Noda, 1994),
two AP-1 sites, and a region called the osteocalcin box
(-99 to -76) that contains a CCAAT motif and overlapping
MSX-I binding site (Lian et al., 1989). Also included is a
typical TATA box at -26 nt which serves as a binding site
for the RNA polymerase-1l-containing transcription initia-
tion complex common to most eucaryotic promoters. Of
these known transcription factor binding sites, particular
attention has been paid to the VDRE and related AP- 1
sites, E-boxes, and the MSX- I site.
The osteocalcin gene was the first shown to be
directly regulated by the steroid hormone, 1,25-dihy-
droxyvitamin D3, and was used to define the first func-
tional VDRE (Kerner et al., 1989; Markose et al., 1990). The
intracellular mechanism used by the 1,25-dihydroxyvita-
min D3:receptor complex to stimulate osteocalcin tran-
scription and the interaction of this complex with other
transcription factors has been recently reviewed (Blanco
et al., 1995; Stein et al., 1996). Interestingly, recent studies
have shown that this well-established response to the
vitamin D hormone may be both developmentally regu-
lated and unique to certain species. For example, a sta-
tistical analysis of the 1,25-dihydroxyvitamin D3
response in cells from 12- vs. 17-day-old embryonic chick
calvariae revealed that osteocalcin was induced by 1,25-
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dihydroxyvitamin D3 in younger, less mature cells and
was inhibited by hormone in older, more osteoblast-like
cells (Gerstenfeld et al., 1996). Species differences have
also been observed; acute 1,25-dihydroxyvitamin D3
treatment induces osteocalcin in rat and human cells
and reduces osteocalcin in mouse cells (Lian et al., 1997).
This difference is explained by sequence differences in
the VDRE-containing region of mouse osteocalcin pro-
moter that render it unresponsive to hormone and by
indirect effects of 1,25-dihydroxyvitamin D3 on the tran-
scription factor, Osf2 (see below) (Clemens et al., 1997; R
Zhang et al, 1997).
The AP- I sites bind members of the fos/jun family of
transcription factors. Although they are not involved in
the osteoblast-specific expression of the osteocalcin
gene, AP-l sites may be important for suppression of
transcription during the proliferative phase of osteoblast
development and complement the activity of osteoblast-
specific factors to permit transcription after cell growth
arrest (McCabe et al., 1995; Stein et al., 1996). Thus, c-fos
and c-jun are expressed at high levels during the prolif-
erative phase and decrease with cell growth arrest and
differentiation, while fra-l and junB increase or remain at
high levels during differentiation. Consistent with the
hypothesis that c-fos may suppress osteocalcin tran-
scription during the proliferative phase, overexpression
of this protein by transfection of ROS 17/2.8 cells with a c-
fos expression vector inhibits osteocalcin expression
(Schule et al., 1990).
The presence of two E-box sequences within the
proximal osteocalcin promoter suggested a possible role
of bHLH transcription factors in osteoblast differentia-
tion analogous to the myoD family of factors in muscle
formation. Previous studies had, in fact, detected several
non-tissue-specific bHLH proteins in osteoblasts and
showed that they can be regulated by calcitropic factors
(Ogata and Noda, 1991; Murray et al., 1992, 1993; Ogata et
al, 1993; Benson et at., 1995). In addition, forced expres-
sion of Id 1, an inhibitory bHLH protein known to inter-
fere with the activity of tissue-specific bHLH proteins in
other systems (Benezra et al., 1990), was reported as par-
tially blocking osteoblast differentiation and osteocalcin
promoter activity (Murray et al., 1992; Tamura and Noda,
1994). Mutagenesis of the downstream E-box (designat-
ed OCEI) at nucleotide -102 reduced osteocalcin pro-
moter activity in ROS 17/2.8 cells by 50%. Furthermore,
an uncharacterized putative bHLH protein present in
nuclear extracts from osteosarcoma cells specifically
bound this E-box. Binding activity which was low in
undifferentiated mesenchymal cells was reported to be
strongly induced by BMP-2 (Tamura and Noda, 1994).
However, more recent studies showed that the nuclear
factor binding to OCEI is widely distributed in many
non-osteogenic tissues and cell lines and has minimal
transcriptional activity when placed 5 to a minimal
mouse osteocalcin promoter (Ducy and Karsenty, 1995).
Furthermore, stable transfection of MC3T3-EI mouse
pre-osteoblast cells with the rat osteocalcin promoter
containing a mutation in OCEI did not affect the devel-
opmental upregulation of this promoter as cells differen-
tiated in culture (Quarles et al., 1997). Thus, bHLH pro-
teins are not likely to play a major role in the osteoblast-
specific expression of the osteocalcin gene, at least in
cultured cells. However, this class of factors may be
involved in earlier steps of bone formation For example,
during development, the recently discovered bHLH fac-
tor, scleraxis, is expressed at high levels within mes-
enchymal precursors of the axial and appendicular skele-
ton in a pattern that pre-figures cartilage anlage forma-
tion. Scleraxis levels then decline prior to overt cartilage
formation and are not subsequently detected in
osteoblasts (Cserjesi et al., 1995). Thus, scleraxis or relat-
ed factors may be involved in the early commitment of
cartilage progenitors.
As noted above, homeobox genes play an important
role in the specification of skeletal structures. The MSX
genes (MSX-1 and MSX-2) have demonstrated roles in
craniofacial and tooth development. Furthermore, muta-
tions in the MSX-2 locus cause the autosomal-dominant
disease, cranial synostosis (labs et al., 1993; Satokata and
Maas, 1994; Chen Y, et al., 1996). For these reasons, the
presence of an MSX site in the osteocalcin promoter was
of particular interest. MSX-2 mRNA is preferentially
expressed in several osteoblast cell lines and primary
cultures, while little or no message is detected in sever-
al types of non-osteoblastic mesenchymal cells
(Hodgkinson et at., 1993; Towler et al., 1994; Heinrichs et
al., 1995). In addition, the MSX site in the rat osteocalcin
promoter specifically binds recombinant MSX-2 protein
and related proteins present in ROS17/2.8 cell nuclear
extracts. However, functional studies on the role of MSX
proteins in osteocalcin gene expression are equivocal.
On one hand, mutations in the MSX site of the rat osteo-
calcin promoter reduced transcriptional activity by
approximately 50%, and suppression of MSX-1 and -2
protein levels with antisense oligonucleotides partially
inhibited mineralized nodule formation and osteocalcin
levels in primary osteoblast cultures, yet forced expres-
sion of MSX-2 suppressed promoter activity (Towler et al.,
1994). Interpretation of these results is further compli-
cated by the fact that MSX proteins are known to partic-
ipate in protein:protein interactions with other homeo-
proteins such as the Dlx family and can inhibit transcrip-
tion by binding to other transcription factors rather than
acting through a specific DNA element (H Zhang et al.,
1997). In conclusion, although MSX proteins are clearly
expressed in osteoblasts and contribute to the activity of
the osteocalcin promoter, other factors are clearly
451O.l) 40 57 1999)
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required to explain the highly bone-selective pattern of
expression of this gene. These results are in contrast to
recent transgenic analysis of the pro&l(I) collagen pro-
moter, which identified a 13-bp region between -1683 and
-1670 bp containing an Msx2 binding site that was essen-
tial for expression in osteoblasts (Dodig et al., 1996a).
To gain a more complete understanding of gene
expression in bone, Ducy and Karsenty initiated a series of
investigations to examine, systematically, the proximal 1.3
kb of the mouse osteocalcin promoter for osteoblast-spe-
cific elements (Ducy and Karsenty, 1995). Murine and
rodent osteocalcins are encoded in two genes. In mice,
osteocalcin genes 1 and 2 are contained in a gene cluster
which also contains a third member, osteocalcin-related
gene, which is expressed only in the kidney (Desbois et at.,
1994). Systematic deletion analysis of the osteocalcin
gene 2 promoter in ROS 17/2.8 cells revealed no major
loss of activity between -1300 and -147 bp from the tran-
scription start site (Ducy and Karsenty, 1995). The -147
promoter retained information necessary for osteoblast-
specific expression, since it was expressed at high levels in
ROS17/2.8 cells, but showed low to undetectable activity
in C2/C12 myoblasts, F9 teratocarcinoma cells, and S194
myeloma. Further deletion to -34 bp completely abolished
promoter activity. DNase I protection assays with ROS
17/2.8 nuclear extracts and the -147 promoter revealed
three major protected regions, designated osteoblast-spe-
cific element 1 (OSE1) between -64 and -47 nt, OSE2
between -146 and -132 nt, and OCEl (which contains the
E-box described above) between -110 and -83 nt. Gel
retardation assays with double-stranded oligonucleotides
containing each sequence and nuclear extracts from ROS
cells and primary mouse osteoblasts revealed that both
OSE I and OSE2 specifically bound nuclear factors, desig-
nated osteoblast-specific factor 1 (Osfl) and Osf2, that
were selectively expressed in osteoblast-like cells. In con-
trast, OCEI bound a factor or factors expressed in a wide
variety of cell types. Deletions in the -147 bp promoter
that removed OSE2 and OSEl drastically reduced pro-
moter activity, while OCEl deletion was without effect.
Furthermore, multiple copies of either OSEl or OSE2
selectively stimulated activity of the minimal -34 bp pro-
moter in osteosarcoma cells (greater than 200-fold stimu-
lation), but not in C2/C12 or F9 cells, while minimal activ-
ity was detected with multimers of the OCEI sequence.
Mutational analysis defined the minimal OSE2 sequence
as CCAACCAC. This study provided the first strong func-
tional evidence that osteoblast-specific enhancer
sequences were present in the osteocalcin promoter.
The initial clue to the identification of the transcrip-
tion factor binding OSE2 came from the laboratories of
Stein and Lian, who had previously identified two
sequences between -605 and -599 nt and -459 and -434 nt
in the rat osteocalcin promoter that specifically bound
osteoblast nuclear proteins. The factor binding these two
regions was called nuclear matrix protein 2 (NMP2),
because it could be extracted from this nuclear fraction.
The NMP2 component interacting with the -605 to -599
region was detected in osteoblast-like cells, but not
hepatoma, promyelocytic leukemia, or cervical carcinoma
cells (Bidwell et al., 1993). Methylation protection assays
identified the upstream NMP2 binding site as 5-ACCACT-
3'. This sequence was originally thought to be a binding
site for CCAAT box-binding factors, but, as was later point-
ed out, it also resembles the consensus sequence for the
AML/runt domain family of transcription factors which
bind the DNA consensus sequence: 5 -PuCCPuCA-3
(Merriman et al., 1995). Pebp2 (polyoma enhancer binding
protein) is the murine homologue of the human acute
myelogenous leukemia (AML) transcription factor family.
The rat osteocalcin promoter also contains a third down-
stream AML/runt site equivalent to the OSE2 site previ-
ously defined in the mouse promoter (Ducy and Karsenty,
1995). Although the two upstream NMP2 binding sites of
the rat osteocalcin promoter served as the basis for the
first identification of AML/runt domain transcription fac-
tors in bone, to date neither site has been shown to have
functional activity in stimulating osteocalcin promoter
activity. In the mouse promoter, the most 5' site between
-608 and -602 nt is not necessary for osteoblast-specific
activity in vivo (Frendo et al., 1998). Subsequent analysis by
both the Karsenty (Baylor College of Medicine, Houston)
and Stein/Lian laboratories (University of Massachusetts
Medical School, Worcester) showed that the downstream
AML site could bind in vitro-translated AML1 protein
(Geoffroy et al., 1995; Banerjee et al., 1996). Furthermore,
AML1 activated transcription of osteocalcin promoter-
reporter gene constructs when transfected into fibroblasts
or F9 teratocarcinoma cells. Finally, the AML-like protein
in osteoblast nuclear extracts could interact with an anti-
AML1 antibody, indicating that the bone protein was a
member of this family. AML-like proteins had previously
been extensively characterized in both humans and mice,
principally because a chromosomal translocation in the
AML1 locus is frequently found in human leukemias
(Meyers et al., 1993). These transcription factors are related
to the Drosophila pair-rule protein, runt, a molecule required
for insect segmentation (Gergen and Wieschaus, 1985). All
function as dimers of cx and J3 subunits. Three a subunits
have been identified and given separate designations in
humans and mice: Human AML1 corresponds to murine
Pebp2oxB/Cbfa2, AML2 to murine Pebp2cxC/Cbfa3, and
AML3 to Pebp2cxA/Cbfal. In addition, two 3 subunits,
Pebp2p3I and PebpP2, have been identified in the mouse
and form dimers with the cx subunits that are obligatory for
transcriptional activation (Sasaki et al., 1996).
Definitive identification of the AML-like protein in
osteoblasts was recently provided by the Karsenty labora-
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tory (Ducy et al., 1997). Using low-stringency hybridization
of an osteoblast cDNA library with a Cbfal runt domain
probe, they isolated a cDNA, sequenced it, and showed it
to be identical in its 3 end to Cbfal (AML3), a molecule
originally cloned from a T-cell library. The protein-coding
portion of this sequence contains both the proline/ser-
ine/threonine-rich and runt domains of Cbfal. More
detailed analysis identified a 19-amino-acid N-terminal
region in the Osf2/Cbfal sequence cloned from
osteoblasts that was not reported in the original Cbfal
cDNA (Thirunavukkarasu et al., 1998). Extensive
structure/function analysis of Osf2/Cbfa 1 identified several
domains necessary for transcriptional activity, including a
myc-related nuclear localization signal, three transcription-
al activation domains, and a repression region. Osf2/Cbfa I
has several properties expected of an osteoblast-specific
transcriptional regulator, including ability to activate the
osteocalcin and osteopontin promoters through an AML
sequence, selective expression in osteoblasts and
osteosarcoma cells, upregulation in mesenchymal cells
after induction of osteoblast differentiation with BMPs,
and, most importantly, ability to induce multiple
osteoblast marker genes lproc I(I) collagen, osteopontin,
bone sialoprotein, and osteocalcinl when transfected into
mesenchymal cell lines such as C3HlOTl/2 cells or undif-
ferentiated murine MC3T3EI pre-osteoblast cells. In addi-
tion, blocking Osf2/CbfaI expression with antisense
oligonucleotides inhibited proc- I(I) collagen, osteopontin,
and osteocalcin expression and mineralized nodule for-
mation (Banerjee et al., 1997; Ducy et al., 1997). Of further
interest, binding sites for Cbfal were detected in promo-
ter regions of osteoblast marker genes, although it has not
yet been demonstrated that all of these sites are function-
al. In fact, Osf2/Cbfal may actually regulate some
osteoblast-related genes through an indirect mechanism
(see below).
A final intriguing property of AML family members is
their ability to interact with the nuclear matrix, a filamen-
tous ribonucleoprotein network thought to provide the
underlying structure for higher-order nuclear organization
into RNA polymerase 11-containing transcription foci
(Nickerson et at., 1995). A recent study by Zeng and co-
workers identified a 31-amino-acid region in AMLIB nec-
essary for nuclear matrix binding that could be distin-
guished from the DNA binding domain (Zeng et al., 1997).
The presence of a related sequence in AML3 (Osf2/Cbfal)
suggests that this transcription factor may activate genes
like osteocalcin by controlling their chromatin organiza-
tion with respect to the transcriptional apparatus.
Role of Osf2/Cbfal in Osteoblast Development
and Genetic Diseases of Bone
While it is not clear that Osf2/Cbfa I alone can induce the
full repertoire of osteoblast activities in mesenchymal
cells (i.e., direct induction of all known markers and for-
mation of a mineralized ECM), this molecule clearly is a
major determinant of the osteoblast phenotype. In situ
hybridization studies of developing mouse embryos first
detected Osf2/Cbfal mRNA in mesenchymal condensa-
tions of the axial and appendicular skeleton and skull on
embryonic day 12.5 (Ducy et al., 1997). A similar pattern
of 3-galactosidase expression was found in transgenic
animals containing a LacZ insert in the CBFAI locus
(Otto et al., 1997). The Osf2/Cbfal-positive cells at this
stage also contain markers for initial cartilage condensa-
tions which suggest that they represent a common pre-
cursor for both chondrocytes and osteoblasts. At later
times (embryonic days 14.5 and 16), Osf2/Cbfal is found
only in osteoblast precursors.
In the same exciting issue of the journal, Cell, that
reported the cloning of Osf2/Cbfa 1, two papers described
the phenotype of CBFAI-deficient mice (Komori et al.,
1997; Otto et al., 1997), and a third demonstrated that
mutations in the human gene cause the genetic disorder,
cleidocranial dysplasia (Otto et al., 1997). CBFAI-null
mice were generated by homologous recombination, and
both heterozygous and homozygous animals were found
to have severe skeletal abnormalities. The phenotype of
the CBFA1 -/- animals was particularly remarkable:
Animals were smaller than their heterozygous or wild-
type littermates, and their skeletons were almost com-
pletely devoid of mineralized bone. In contrast, cartilage
formation was not grossly affected by the mutation. The
skeletons of heterozygotes exhibited a severe hypoplasia
of the clavicle and delayed development of the membra-
nous bones of the skull, resulting in open anterior and
posterior fontanelles and wide cranial sutures. In situ
hybridization and Northern blot analysis failed to detect
osteocalcin in the osteoblasts of CBFA -/- animals.
Interestingly, osteocalcin and alkaline phosphatase
could be induced in calvarial cells from mutant animals
if they were treated with high concentrations of BMP-2
(Komori et al., 1997). This suggests that factors in addi-
tion to Cbfal play important roles in the induction of
these genes by BMPs, at least in cell culture.
The phenotype of heterozygotic CBFA1 mutants is
remarkably similar to the human disease, cleidocranial
dysplasia (CCD), an autosomal-dominant disorder char-
acterized by the absence or near-absence of the clavicles,
open fontanelles, supernumerary teeth, and short
stature. In fact, two lines of evidence now show that the
CBFA1 gene is mutated in this disease. First, the CBFA1
locus on mouse chromosome 17 is deleted in the Ccd
mouse, a radiation-induced mutant with a phenotype
similar to human CCD patients (Otto et al., 1997). Second,
the human CCD locus and CBFA1 have been co-localized
to chromosome 6p2 1, and several CCD families have
4710(1)40 57(1999)
Oral Biot Med
Crit Rev Oral Biol Med10(i1):40-57 (1 999)
been identified in which the CBFA1 gene is deleted or
contains insertion, deletion, or missense mutations (Lee
et al., 1997; Otto et al., 1997). The conclusion from these
studies is that CCD exhibits a dominant form of inheri-
tance, because it is caused by loss of function mutations.
These are generally lethal in homozygotes and cause
CCD in heterozygotes because of haplo-insufficiency.
Regulation of the Bone Sialoprotein Gene
Bone sialoprotein, a highly acidic bone phosphoprotein
with a possible role in ECM mineralization (Hunter and
Goldberg, 1993), is also preferentially expressed in
osteoblasts, although it has a somewhat broader tissue
distribution than osteocalcin. BSP is found at high levels
in mature osteoblasts, but not their immature precursors,
hypertrophic chondrocytes, odontoblasts, cementoblasts,
and, to a lesser extent, osteoclasts, trophoblasts, and cer-
tain metastatic cancers (Bianco et at., 1991; Chen et at.,
1993; MacNeil and Somerman, 1993; Bellahcene et al.,
1996). The BSP gene has been cloned from rat (Li and
Sodek, 1993), mouse (Benson et al., 1997), human (Kerr et
al., 1993; Kim et al., 1994), and avian species (Yang and
Gerstenfeld, 1997). An approximately 2.7-kb sequence of
the rat BSP promoter driving expression of a firefly
luciferase reporter gene was analyzed in transgenic ani-
mals and was shown to be selectively expressed in bone
osteoblasts, with negligible expression in the kidney, liver,
stomach, intestine, and spleen (Chen J, et al., 1996). Thus,
important elements for osteoblast-selective expression
are contained in this promoter region. Inspection of the
proximal BSP promoter from mammalian species reveals
a high degree of sequence conservation, particularly in the
first approximately 370 nt upstream from the transcription
start site (ca. 75% sequence identity across rat, mouse, and
human promoters). This region contains a number of pre-
viously characterized DNA sequences, including an invert-
ed TATA box with overlapping VDRE, a CCAAT box, a type
11 collagen-like silencer, and putative binding sites for the
transcription factors CREBP (cAMP response element
binding protein), NFKB, and fos/jun (AP-1), as well as two
homeobox domains (MSX-2 and Engrailed- 1) (Sodek et at.,
1996; Yang and Gerstenfeld, 1997). The VDRE and a distal
glucocorticoid regulatory element have both been shown
to have modest activity in vivo and in cell culture (Ogata et
at., 1995; Sodek et al., 1995). The chicken BSP promoter is
also stimulated approximately five-fold by PTH, and this
response is mediated by a CRE half-site (Yang and
Gerstenfeld, 1996). Although the chicken promoter shares
less overall homology with mammalian BSP promoters,
many of the above-listed regulatory elements are con-
served, including the two homeobox sites and the colla-
gen silencer region, suggesting that they have important
roles in regulation (Yang and Gerstenfeld, 1997).
Only recently has substantial progress been made in
the functional definition of specific elements in the BSP
promoter necessary for osteoblast-specific expression.
Initial studies in which 2.7 kb of the rat promoter was
transiently transfected into osteoblast-like vs. fibroblastic
cells revealed little preferential expression in osteoblasts
(Sodek et at., 1994). More recent studies with a 1.2-kb frag-
ment of the chicken promoter showed preferential
expression in osteoblasts and cephalic chondrocytes
when compared with skin fibroblasts (Yang and
Gerstenfeld, 1997). Some of this specificity was attributed
to a suppression of promoter activity in fibroblasts, pos-
sibly via the collagen II silencer in the region between -966
and -949 bp. Preliminary studies from the author's labo-
ratory show approximately 20-fold higher expression of a
2.5-kb fragment of the mouse BSP promoter in
osteoblasts relative to C2/C12 myoblasts, 3T3-L1
adipocytes, F9 teratocarcinoma cells, and S194 leukemia
cells (Benson et al., 1997). Deletion analysis revealed
much of the tissue specificity to reside in a region
between - 173 and -334 nt upstream from the transcription
start site. Deletion of the region containing the collagen
II silencer did not increase promoter activity in non-bone
cells. Of further interest, although consensus binding
sites for AML family members are present in the BSP pro-
moter from all species examined, none is contained in
the -173 to -334 region. This suggests that the induction
of BSP mRNA by Osf2/Cbfal, noted above (Ducy et al.,
1997), may be through an indirect mechanism.
Extracellular Matrix Regulation
of Osteoblast-specific Gene Expression
The extracellular matrix (ECM) plays an essential if often
overlooked role in osteoblast differentiation. As a cell
primarily devoted to matrix production, the osteoblast
must have the ability to monitor the composition of the
ECM it is secreting as well modify matrix production to
accommodate the changing mechanical needs of bone. It
is not known how this is accomplished. However, there is
now strong evidence that osteoblast differentiation and
collagen matrix secretion are closely linked. An appreci-
ation for the significance of the ECM in osteoblast func-
tion may be gained from an examination of the require-
ment for ascorbic acid (AA, reduced vitamin C) in
osteoblast differentiation. AA is an essential co-factor for
hydroxylation of procollagen chains, a necessary step for
triple helix formation, secretion, and collagen fibril
assembly. Thus, in vitamin C deficiency, collagen matrix
production is essentially blocked. In vivo, both bone for-
mation and osteoblast differentiation, as assessed by
expression of osteocalcin and alkaline phosphatase
mRNAs, are severely reduced in animals on vitamin-C-
deficient diets (Togari et al., 1995; Mahmoodian et al.,
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1996). This requirement is also seen in vitro, where AA is
essential for differentiation and mineralization of primary
osteoblast cultures and nontransformed osteoblast-like
cell lines such as murine MC3T3-E1 cells (Gerstenfeld et
al., 1987; Owen et al., 1990; Franceschi and Iyer, 1992;
Ibaraki et al., 1992; Quarles et al., 1992; McCauley et al.,
1996). AA responsiveness is a unique property of non-
transformed cells and is not observed in osteosarcoma
cell lines such as the ROS 17/2.8 cells used in many of the
studies described above to characterize the osteocalcin
promoter. These cells express high levels of osteoblast
markers in the absence of AA, which suggests either that
an important level of regulation has been lost in this
osteosarcoma cell line or that ROS17/2.1 cells have pro-
gressed beyond the point in the osteoblast lineage where
ECM synthesis is required for phenotypic expression.
Studies from the author's laboratory have demonstrated
that actions of AA on osteoblast differentiation are medi-
ated by the collagenous matrix (Franceschi and lyer, 1992;
Franceschi et al., 1994). Disruption of matrix secretion with
specific inhibitors or enzymatic digestion of secreted col-
lagen blocks the induction of osteoblast-related genes. A
similar requirement for collagen synthesis was recently
demonstrated in retinoic-acid-treated ROB-C26 cells, a
multipotential mesenchymal cell line (Shi et al., 1996).
Studies on the genetic disease osteogenesis imper-
fecta (01) further support the importance of the ECM
environment in osteoblast function. The majority of 01
mutations are in glycines that occupy every third residue
in the helical region of type I collagen or are deletions in
the triple helical domain. The consequences of these
mutations may, to various degrees, be similar to the situ-
ation encountered in AA deficiency: Procollagen triple-
helix structure is destabilized with accompanying
decreased rates of secretion, processing and cross-link-
ing, and abnormal fibril assembly. These defects would, in
turn, compromise the ability of cells to differentiate nor-
mally. In fact, osteopenia due to reduced extracellular
matrix synthesis is a hallmark of 01, and osteoblasts cul-
tured from 01 patients exhibit reduced synthesis of colla-
gen and proteoglycan (Fedarko et al., 1992, 1996). To
examine more directly the effect of abnormal collagen
structure on osteoblast differentiation, Wenstrup and co-
workers created MC3T3-E I cell lines that stably expressed
a human proox1(l) collagen minigene with a truncated
triple helical domain known to cause an 01 phenotype in
transgenic mice (Wenstrup et al., 1996). As predicted from
studies with AA-deficient cells, osteoblasts containing
this abnormal collagen exhibited rapid matrix turnover,
severely abnormal collagen fibrillogenesis, and
decreased levels of alkaline phosphatase and bone sialo-
protein. However, osteocalcin levels were actually elevat-
ed, indicating that this matrix abnormality affects osteo-
calcin differently from other osteoblast markers.
More recent studies focused on the relationship
between matrix synthesis and induction of osteoblast-
specific gene expression, with the well-characterized
mouse osteocalcin gene 2 as a model (Xiao et al., 1997).
ECM synthesis increased promoter activity approximate-
ly 20-fold in MC3T3-E1 cells. Significantly, this response
was shown to require OSE2, the downstream promoter
binding site for the transcription factor Osf2/Cbfa 1.
Mutation or deletion of this element abolished activity.
Furthermore, OSE2 oligomers in the absence of other
promoter elements were able to confer matrix respon-
siveness on a -34-nt minimal osteocalcin promoter con-
struct. Although deletion analysis suggested that other
upstream regions of the osteocalcin promoter between
-657 and -147 may also contribute to ECM responsive-
ness, the downstream OSE2 site is clearly essential,
because a point mutation in this element abolished the
AA responsiveness of a -657 promoter construct. AA
treatment was also accompanied by a five-fold increase
in the binding of Osf2/Cbfal to OSE2. Thus, ECM syn-
thesis stimulates osteoblast-specific transcriptional
activity in part by activating/upregulating the tissue-spe-
cific transcription factor, Osf2/Cbfa 1. We do not currently
know if this mechanism explains the upregulation of
other genes by AA. However, like osteocalcin, the bone
sialoprotein promoter is upregulated by AA and may be
subjected to similar controls (Benson et al., 1997).
Ongoing studies in the author's laboratory and else-
where are exploring possible mechanisms to explain how
the collagenous ECM can stimulate osteoblast-specific
gene expression. Several years ago, we proposed a gener-
al model for ECM regulation of osteoblast differentiation
in which the matrix was viewed as interacting with the cell
surface through specific integrins to initiate intracellular
signaling pathways leading to osteoblast-specific gene
expression (Franceschi, 1992). Integrins are the principal
mediators of the molecular dialogue between a cell and its
ECM environment and are crucial to processes such as tis-
sue morphogenesis, wound healing, and cell migration
and attachment (for reviews, see Clark and Brugge, 1995;
Gumbiner, 1996). All function as dimers composed of an (x
and a 3 subunit. The unique combinations of subunits
determine which ECM molecules will be recognized by a
cell. For example, type I collagen interacts with both a-,j3
and u2fi, integrins, while fibronectin binds t3, -4, and a5:
,B, dimers. Integrins convey information about the extra-
cellular environment both by serving as a direct physical
link between the ECM and actin cytoskeleton via the pro-
teins, talin, vincullin, and paxillin, and by functioning as
signal transduction molecules to stimulate tyrosine phos-
phorylation cascades involving the mitogen-activated pro-
tein kinase (MAP kinase) and other pathways (Roeckel and
Krieg, 1994; Sudbeck et al., 1994; Lin et al., 1997).
Recently, considerable evidence has accumulated
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Figure 3. Model for extracellular matrix activation of the osteocalcin promoter. Key com-
ponents of this model are: (1) the interaction of the type collagen matrix with the etA
integrin, followed by signaling to the nucleus; (2) phosphorylation and activation of
Osf2/Cbfal and possibly other transcription factors; and (3) binding of Osf2/Cbfal to
AML sites in the osteocalcin promoter and stimulation of transcription. Several known
integrin-mediated signal transduction pathways are shown (Clark and Brugge, 1995;
Gumbiner, 1996), although those relevant to osteoblast function have not been defined.
Also indicated is the physical linkage between integrins and the cytoskeleton via cx-actinin
and the actin filaments, which may also control transcription. Not shown is the possible
role of nuclear organization in the activation of Osf2/Cbfal. It has been proposed that
this factor can associate with the nuclear matrix as well as with AML sites in the osteo-
calcin promoter, thereby bringing the promoter into contact with the basal transcription
initiation complex. Abbreviations: ox2p1, integrin subunits known to form a receptor for
type collagen; DGEA, Asp-Gly-Glu-Ala sequence of type collagen, reported to inter-
act with the ox2P1 integrin; FAK, focal adhesion kinase; Osf2, Osf2/Cbfal transcription
factor; AML, DNA binding site for AML/runt transcription factors (positions in the mouse
osteocalcin gene 2 promoter are indicated); and TFs, components that, together with
RNA polymerase 11, form the basal transcription initiation complex.
supporting a role for integrins in
osteoblast differentiation. Osteoblasts are
now known to express several integrin
species, including Up, (X2, C3 Ct4aC5,C 1'
(2, and 33 subunits (Clover et al., 1992;
Hughes et al., 1993; Grzesik and Gehron-
Robey, 1994; Saito et al., 1994; Sinha and
Tuan, 1996). Furthermore, disruption of
integrin:ECM interactions, specifically
those involving collagen and fibronectin,
blocks osteoblast differentiation and min-
eralization. Thus, addition of antibodies to
a2 integrin or a DGEA peptide which is a
component of the cell-binding domain of
type I collagen (Staatz et al., 1991) blocks
AA-dependent induction of alkaline phos-
phatase and differentiation-dependent
down-regulation of TGF-( receptors in
MC3T3-E1 cells (Takeuchi et al., 1996).
These responses appear to require focal
adhesion kinase and the MAP kinase path-
way, because selective inhibition of either
of these intermediates blocks alkaline
phosphatase induction (Takeuchi et al.,
1997). In separate studies, a peptide con-
taining the RGD cell-binding domain of
fibronectin was shown to inhibit both
bone formation and resorption in a miner-
alizing organ culture system (Gronowicz
and Derome, 1994). Similarly, long-term
culture of calvarial osteoblasts with anti-
fibronectin antibodies or fibronectin pep-
tides containing the RGD cell-binding
domain has also been reported to sup-
press differentiation (Moursi et at., 1996).
The author's laboratory recently showed
that disruption of CX2 integrin function by
both anti-a2 integrin antibody and DGEA
peptide also blocks ascorbic-acid-depen-
dent induction of the osteocalcin promo-
ter, osteoblast differentiation, and activa-
tion of Osf2/Cbfal (Xiao et al., 1998a). The
same concentrations of anti-(x5 integrin
antibody or RGD-containing peptide were
inactive, although the RGD peptide was
inhibitory at higher concentrations.
Interestingly, the dramatic matrix-depen-
dent increase in Osf2/Cbfal binding to
OSE2 noted above is not accompanied by
parallel changes in the level of transcrip-
tion factor mRNA or protein. This suggests
that the ECM induces a modification in
Osf2/Cbfal to increase its activity as a
transcriptional enhancer rather than
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increasing protein levels. In a related study, overexpression
of the c.2 integrin subunit in primary calvarial osteoblast
cells also greatly increased osteocalcin promoter activity
(Zimmerman et al., 1997).
Recent preliminary results from the author's laboratory
indicate that Osf2/Cbfa I is phosphorylated by MAP kinases
and that this modification stimulates transcriptional activi-
ty (Xiao et al., 1998b).
Taken together, these results strongly support a model
in which an CX2031 integrin:type I collagen interaction is nec-
essary for phosphorylation and activation of osteoblast-
specific transcription factors like Osf2/Cbfal present in
committed osteoprogenitor cells. There are several exam-
ples of type I collagen: oL2A integrin interactions being
important in the regulation of other cellular activities, such
as activation of collagenase (Riikonen et al., 1995), stimula-
tion of collagen gel contraction (Schiro et al., 1991), and kid-
ney tubule formation (Schwimmer and Ojakian, 1995),
although in no case has the entire integrin-mediated path-
way been delineated. Clearly, a major direction for future
research will be to identify the signal transduction pathway
linking integrin:ECM binding to changes in osteoblast-spe-
cific gene expression and to determine how this pathway is
regulated by changes in matrix synthesis and turnover,
mechanical loading of bone, and the hormonal milieu. Fig.
3 summarizes our current thinking about how the ECM reg-
ulates gene expression in osteoblasts.
Is the Tooth a Kind of Bone?
At the molecular level, dentin and cementum share many
similarities with bone, including the presence of a min-
eralized type I collagen matrix and noncollagenous pro-
teins such as osteocalcin, bone sialoprotein, alkaline
phosphatase, and BMPs (MacNeil and Somerman, 1993;
Lesot et al., 1994). In fact, because no unique markers
have been identified to distinguish it from bone, it has
been proposed that the cementoblast may actually be a
specialized type of osteoblast (MacNeil et al., 1998). In
contrast, odontoblasts do express at least two unique
proteins, dentin sialoprotein and dentin phosphopro-
tein, which were recently shown to be synthesized as a
single transcript (MacDougall et al., 1997). Like
osteoblasts, cementoblasts and odontoblasts require
ascorbic acid to express a differentiated phenotype
(D'Errico et al., 1997; Heimrika-Wagner et al., 1982), and it
is likely that cellImatrix interactions shown to be crucial
for osteoblast differentiation are also necessary for
dentin and cementum formation. A central question
concerns the degree to which genetic mechanisms con-
trolling osteoblast differentiation are relevant to our
understanding of odontoblasts and cementoblasts. For
example, is Osf2/Cbfa 1 an important factor for determina-
tion of these cell types, or are other transcription factors
involved? Individuals with cleidocranial dyplasia have
teeth-extra teeth in fact-but this may be a consequence
of their heterozygous status for the CBFA1 gene. CBFA1 -/-
mice contain hypoplastic tooth primordia, although the
appropriate cell layers of differentiating tooth structures
were present (Otto et al., 1997). It was not determined
whether these structures express osteocalcin or other
matrix proteins. A comparison of the transcriptional regu-
lation of genes like osteocalcin, bone sialoprotein, and
dentin sialophosphoprotein in bones with that in teeth
may reveal important information about more subtle reg-
ulatory mechanisms that distinguish these two similar, yet
functionally very different, tissues.
Conclusions and Future Directions
The organogenesis of skeletal structures can be divided
into two broad phases: the establishment of a mor-
phogenic field in which signals from organizing centers
like the ZPA specify in time and space which cells are
destined to form bone, followed by a differentiation
phase when gene expression patterns are altered in
response to coded positional information to produce
chondrocytes and osteoblasts at sites of overt bone for-
mation. Although this article focused on gene regulation
during osteoblast differentiation, much progress has
also been made in our understanding of these early mor-
phogenic signals. The combined use of promoter analy-
sis and transgenic technology has allowed our under-
standing of gene expression in bone to progress rapidly.
A striking example of this rapid pace of discovery was the
simultaneous publication of the identification, targeted
inactivation, and human genetics of Osf2/Cbfal.
Undoubtedly, this rate of progress will only increase in
the coming years. Some of the more outstanding
research questions to be addressed in the next five years
are summarized below:
(I) How DO EARLY PATTERNING EVENTS INITIATED
BY FACTORS LIKE SHH LEAD TO THE FORMATION
OF BONE AT SPECIFIC SITES?
Hox gene expression is known to precede mesenchymal
condensations in regions targeted for future bone forma-
tion, but it remains to be determined how these sites are
specified and distinguished from areas destined to form
non-osseous structures.
(11) IS OSF2/CBFAI THE ONLY TRANSCRIPTION
FACTOR REQUIRED FOR OSTEOBLAST-SPECIFIC
GENE EXPRESSION, OR IS IT ONLY ONE OF
SEVERAL COMPONENTS, PERHAPS AN ENTIRE
FAMILY OF OSTEOGENIC NUCLEAR FACTORS,
THAT WORK IN A CONCERTED FASHION TO
CONTROL TRANSCRIPTION?
An understanding of the full range of transcriptional
controls necessary for osteoblast-specific gene expres-
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sion will require the systematic analysis of multiple gene
promoters.
(111) WHAT ARE THE RELEVANT PATHWAYS FOR
ACTIVATION OF OSF2/CBFAI?
Osteoblast cultures grown in the absence of AA contain
Osf2/Cbfa 1, but the transcriptional activity of this factor
remains low until cells are allowed to synthesize an ECM.
Preliminary studies suggest the involvement of an integ-
rin-mediated event for Osf2/Cbfal activation, but the
details of this pathway remain to be determined.
(IV) ARE THE TRANSCRIPTIONAL CONTROLS
IDENTIFIED IN BONE FOUND IN OTHER
MINERALIZED TISSUES SUCH AS TEETH?
Initial reports on tooth formation in Osf2/Cbfal knockout
mice suggest the involvement of this factor in tooth mor-
phogenesis, but it remains to be determined if it func-
tions similarly in bones and teeth. Elucidation of the reg-
ulatory controls for multiple odontoblast-related genes
will be required to discriminate between general and
tooth-specific gene regulatory mechanisms.
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